Stay updated with breaking news from Nasdaq Amph. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amalgamated Bank cut its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) by 5.7% in the 1st quarter, HoldingsChannel reports. The firm owned 16,909 shares of the company’s stock after selling 1,024 shares during the quarter. Amalgamated Bank’s holdings in Amphastar Pharmaceuticals were worth $607,000 as of its most recent filing with […]
Victory Capital Management Inc. lessened its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) by 12.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 62,699 shares of the company’s stock after selling 8,904 shares during the quarter. Victory Capital Management […]
Brokerages expect Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) to post earnings of $0.37 per share for the current quarter, Zacks reports. Two analysts have provided estimates for Amphastar Pharmaceuticals’ earnings. The highest EPS estimate is $0.40 and the lowest is $0.33. Amphastar Pharmaceuticals reported earnings per share of $0.21 in the same quarter last […]
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) Director Howard Lee sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, May 23rd. The shares were sold at an average price of $34.93, for a total value of $349,300.00. Following the transaction, the director now directly owns 138,776 shares of the company’s stock, valued […]
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) has been assigned an average rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year price objective among brokers […]